Idalopirdine Explained

Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT₆ receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.^{[1] [2]} As of October 2013 it is in phase III clinical trials.^[2]

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.^[3] Two further phase III trials failed too, the company confirmed in early 2017.^[3]

See also

• Cerlapirdine
• Latrepirdine

External links

• Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
• Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease

Notes and References

1. Web site: U.S. Development Programs. . Lundbeck .
2. Web site: Search of: Lu AE58054 - List Results . ClinicalTrials.gov . National Library of Medicine, U.S. Department of Health and Human Services .
3. Web site: Taylor NP . 23 September 2016 . PhIII Alzheimer's flop takes chunk out of Lundbeck, hits Axovant with aftershocks .